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Genetic factors have been suggested to be involved in the pathogenesis of sporadic inclusion body
myositis (sIBM). Sequestosome 1 (SQSTM1) and valosin-containing protein (VCP) are 2 key genes asso-
ciated with several neurodegenerative disorders but have yet to be thoroughly investigated in sIBM. A
candidate gene analysis was conducted using whole-exome sequencing data from 181 sIBM patients, and
whole-transcriptome expression analysis was performed in patients with genetic variants of interest. We
identiﬁed 6 rare missense variants in the SQSTM1 and VCP in 7 sIBM patients (4.0%). Two variants, the
SQSTM1 p.G194R and the VCP p.R159C, were signiﬁcantly overrepresented in this sIBM cohort compared
with controls. Five of these variants had been previously reported in patients with degenerative diseases.
The messenger RNA levels of major histocompatibility complex genes were upregulated, this elevation
being more pronounced in SQSTM1 patient group. We report for the ﬁrst time potentially pathogenic
SQSTM1 variants and expand the spectrum of VCP variants in sIBM. These data suggest that defects inuscular Diseases, Department of Molecular Neuroscience, Institute of Neurology, University College London, Queen
68; fax: þ44 20 3448 4786.
), h.houlden@ucl.ac.uk (H. Houlden).
er Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Q. Gang et al. / Neurobiology of Aging 47 (2016) 218.e1e218.e9218.e2neurodegenerative pathways may confer genetic susceptibility to sIBM and reinforce the mechanistic
overlap in these neurodegenerative disorders.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Sporadic inclusion body myositis (sIBM) is the most common
myopathy among people aged >45 years, presenting a character-
istic pattern of progressive muscle weakness and atrophy in both
proximal and distal muscles, particularly in knee extensors and
wrist and ﬁnger ﬂexors (Machado et al., 2014). Muscle pathology in
sIBM indicates a combination of inﬂammatory and degenerative
features such as rimmed vacuoles, sarcoplasmic inclusions, and the
deposition of degenerative proteins in affected muscle as patho-
logic hallmarks, which are features that differentiate sIBM from
other muscle disorders (Machado et al., 2014). Electromyography
shows a myopathic and neurogenic pattern in some sIBM patients
(Lotz et al., 1989), which resembles some hereditary inclusion body
myopathies (hIBMs) andmotor neuron diseases (Dabby et al., 2001;
Lotz et al., 1989). Genes have been identiﬁed as associated with
hIBMs, and genetic susceptibility factors could also be involved in
the pathogenesis of sIBM. In addition to the known hIBM genes,
genes encoding for the proteins abnormally accumulated in sIBM
muscle are of great interest (Gang et al., 2014), as many of these
proteins, such as amyloid-b, hyperphosphorylated tau, p62, and
transactive response (TAR) DNA-binding protein-43 (TDP-43), have
also been associated with neurodegenerative diseases including
Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and
Parkinson’s disease. Furthermore, several studies have shown that
the major histocompatibility complex (MHC)erelated genes are
dysregulated in sIBM (Gang et al., 2014). However, no genetic fac-
tors have yet been conﬁrmed as associated with sIBM (Gang et al.,
2014, 2015).
P62, also known as sequestosome 1 (SQSTM1), has been
recognized as a strong biomarker in muscle with a high sensitivity
and speciﬁcity for sIBM (Brady et al., 2014). Genetic variants in
SQSTM1 had not been investigated in sIBM until a recent study
using targeted next-generation sequencing in a group of 79 patients
(Weihl et al., 2015). In that study, only a common SQSTM1 poly-
morphism was found, unlikely contributing to a rare disease. A
recent study reported a splice donor variant in SQSTM1 in a family
with an autosomal dominant distal myopathy and also in an un-
related patient with sporadic distal myopathy (Bucelli et al., 2015).
In addition, mutations in SQSTM1 are well known to be associated
with familial and/or sporadic Paget disease of bone, ALS, and
frontotemporal dementia (FTD) (Fecto et al., 2011; Kwok et al.,
2014; Laurin et al., 2002; Le Ber et al., 2013; Miller et al., 2015;
Rubino et al., 2012). Mutations in valosin-containing protein (VCP)
gene are known to cause an inherited form of IBM with Paget dis-
ease and frontotemporal dementia (IBMPFD) (Gidaro et al., 2008;
Watts et al., 2004) and have also been reported in cases with ALS
and FTD (Johnson et al., 2010; Koppers et al., 2012). Two missense
mutations in VCP have been recently identiﬁed in 2 unrelated IBM
patients, one with sIBM and another with family history for
late-onset dementia (Weihl et al., 2015).
These ﬁndings, along with denervation in muscle electromyog-
raphy of sIBM patients, suggest a possible genetic overlap between
sporadic and IBM-like myopathies and also neurodegenerative
diseases. To thoroughly investigate the contribution of SQSTM1 and
VCP genes in sIBM, we investigated these 2 genes using whole-
exome sequencing data from 181 sIBM patients, which was
produced as a part of an International IBM Genetics Consortium.2. Materials and methods
2.1. Subjects
This study is part of the International IBM Genetics Consortium,
a Muscle Study Groupeendorsed project, which currently has
members from 17 specialized centers in 7 countries around the
world. For this whole-exome sequencing Consortium study, DNA
samples from a total number of 181 sIBM patients were collected
from 11 centers. Patients diagnosed with sIBM had to have an sIBM
diagnosis according to a muscle diseases expert and also had to
fulﬁl the Griggs criteria (Griggs et al., 1995; Tawil and Griggs, 2002),
the European Neuromuscular Center 2000 criteria (Badrising et al.,
2000), or the MRC 2010 criteria (Hilton-Jones et al., 2010). Neuro-
pathologically healthy controls (N¼ 235) aged>60 years were used
as an internal aged control group to compare with our sIBM cohort.
The study was approved by the National Research Ethics Service
Committee LondondQueen Square (research ethics committee
reference: 12/LO/1557).
2.2. Genetic and bioinformatic analysis
Whole-exome sequencing data were generated for 181 sIBM
DNA samples as previously described (Mencacci et al., 2015). In this
study, we used a candidate gene approach on these whole-exome
sequencing data to investigate variants in SQSTM1 and VCP genes.
We excluded all synonymous variants, and all common variants
with a population frequency >1% were identiﬁed in the 1000
Genomes project (www.1000genomes.org/), in the Exome Variant
Server (EVS) database (evs.gs.washington.edu/EVS/), in the Exome
Aggregation Consortium (ExAC) Browser (exac.broadinstitute.org/),
and in the internal aged controls, as these variants less likely play a
role in a rare disease. The ﬁltered variants were conﬁrmed by the
conventional Sanger sequencing. The allele frequency of each
variant found in sIBM was compared with the ExAC database using
Fisher test. The pathogenicity of these variants was evaluated using
the following in silico prediction tools: SIFT (Kumar et al., 2009),
MutationTaster (Schwarz et al., 2014), and PolyPhen2 (Adzhubei et
al., 2010). Genomic evolutionary rate proﬁling (GERPþþ) scores
were used to estimate the conservation of each variant in multi-
species alignments, with higher scores indicating the most
conserved nucleotide positions (Davydov et al., 2010).
2.3. Messenger RNA expression and real-time quantitative
polymerase chain reaction validation
Available ﬂash frozen muscle biopsy tissues from 6 sIBM sub-
jects with variants in SQSTM1 or VCP and 8 controls that were kindly
provided by the MRC Sudden Death Brain and Tissue Bank in
Edinburgh, UK, were used for the gene expression analysis. Total
RNA was isolated from muscle tissue using the miRNeasy kit (Qia-
gen, Crawley, UK), and the concentration, purity, and integrity of
each RNA sample were assessed as previously described (Trabzuni
et al., 2011).
Whole-genome expression proﬁling was performed using the
Illumina HumanHT-12 v4 Expression BeadChip (Illumina, Inc, USA)
on 3 patients with SQSTM1 variants (cases 1, 3, and 4), 2 patients
with VCP variants (cases 6 and 7), and 5 age- and gender-matched
Q. Gang et al. / Neurobiology of Aging 47 (2016) 218.e1e218.e9 218.e3controls. Raw expression data were log2 transformed and quantile
normalized, and differential expression analysis (patients with
SQSTM1 variants vs. controls and all the patients vs. controls) was
performed using the limma Bioconductor package (Ritchie et al.,
2015). Genes were considered differentially expressed and used in
further analysis, when false discovery rateeadjusted p value was
<0.05 and absolute log2 fold change was >0.2. Functional enrich-
ment analysis for Gene Ontology terms, KEGG (Kyoto Encyclopedia
of Genes and Genomes) pathways, and Human Phenotype Ontology
terms was performed using g:Proﬁler (biit.cs.ut.ee/gproﬁler/).
Among the upregulated genes, 3 genes associated with inﬂamma-
tion markers (HLA-A, CD74, and HLA-DRA) were selected for
validation using real-time quantitative polymerase chain reaction
(RT-qPCR). Brieﬂy, total RNA (600 ng) from the 6 cases and 8 con-
trols was reverse transcribed into complementary DNA using
random primers from High-Capacity cDNA Reverse Transcription
Kit (Applied Biosystems, USA). Three replicates per sample were
assayed for each target gene using Fast SYBR Green PCR Kit (Applied
Biosystems) and run in a QuantStudio 6 Flex Real-Time PCR System
(Applied Biosystems). Details on primers and RT-qPCR conditions
are available on request. Cyclophilin (PPIA) was selected as the
reference gene. The 2DDCt method (Schmittgen and Livak, 2008)
was used for Ct normalization for each gene and determination of
fold changes in gene expression between patients and controls.
Mann-Whitney U test was performed to analyze the difference of
relative gene expression between patient groups and controls. For
all the analyses, p value <0.05 was considered statistically signiﬁ-
cant. Statistical analysis was performed using SPSS Statistics 22
(IBM, USA).
3. Results
From the entire cohort of 181 sIBM patients, 150 (82.9%) were
Caucasians and 16 (8.8%) were from other ethnicities, including
Asian Chinese, the Indian subcontinent, and Black Africans
(ethnicity information was unavailable for 15 patients). The ma-
jority of sIBM patients were male (65.7%). Age of onset, which was
collected retrospectively, ranged from 31 to 85 years (mean 59.6 
9.6 years). The mean age of the 235 healthy aged controls was 79.1
 8.5 years, ranging from 60 to 102 years, and similarly to the sIBM
cohort, the majority were also male (61.7%).
In this sIBM cohort, 4 rare missense variants in the SQSTM1 gene
(ENST00000389805) were found in 4 patients (Table 1). Two rare
missense variants in the VCP gene (ENST00000358901) were found in
3 sIBM patients. Of note, the frequency of the variants SQSTM1Table 1
SQSTM1 and VCP rare genetic variants in patients with sIBM
Case ID Gene and
region
Variants
(heterozygous)
MAF in 235
neuropathologic
controls (%)
MAF in 1000
genomes (%)
Case 1 (sIBM) SQSTM1
Exon 8
p.P392L (rs104893941) 0.213 0.46
Case 2 (sIBM) SQSTM1
Exon 3
p.A117V (rs147810437) 0 0.18
Case 3 (sIBM) SQSTM1
Exon 4
p.G194R 0 d
Case 4 (sIBM) SQSTM1
Exon 5
p.K238E (rs11548633) 0.638 0.32
Case 5 (sIBM) VCP
Exon 2
p.I27V (rs140913250) 0 0.09
Case 6 (sIBM)
Case7 (sIBM)
VCP
Exon 5
p.R159C 0 d
Key: A, alanine; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; C, cysteine;
evolutionary rate proﬁling; I, isoleucine; IBMPFD, inclusion bodymyopathywith Paget dis
P, proline; PD, Parkinson’s disease; PDB, Paget disease of bone; R, arginine; sIBM, sporadic
protein.p.G194R and VCP p.R159C was signiﬁcantly higher in our sIBM cohort
comparedwith the ExAC database (Fisher exact test, p¼ 0.018 and p¼
5.288 105, respectively). These 2 variants were absent in the other
population databases and in our aged control group. From the 6 rare
variant we found, 4 (Table 1) had been previously reported in patients
with ALS (Abramzon et al., 2012; Rubino et al., 2012). Among them,
the SQSTM1 p.P392L is also known to be the most frequent SQSTM1
mutation in PDB (Laurin et al., 2002) and has also been reported in
cases with FTD (Le Ber et al., 2013) and normal tension glaucoma
(Scheetz et al., 2016), whereas VCP p.I27V and p.R159C have also been
found in patients with IBMPFD (Chan et al., 2012; Rohrer et al., 2011),
and the VCP p.I27V has also been recently reported in one sIBM pa-
tient (Weihl et al., 2015). The SQSTM1 p.A117V was reported in one
early-onset AD patient (Cuyvers et al., 2015). Variants found in sIBM
patients were absent in our internal aged controls except SQSTM1
variants previously associated with ALS (p.P392L and p.K238E,
Table 1). With the exception of SQSTM1 p.A117V, all these variants are
located at conserved positions among species further suggesting they
are functionally relevant. The variants found in our cohort and in
previous studies are shown in Fig. 1.
Tables 2 and 3 summarize the demographic, clinical, and muscle
biopsy characteristics of the patients carrying SQSTM1 and VCP var-
iants. The 7 sIBM cases fulﬁlled the MRC 2010 diagnostic category of
pathologically deﬁned, clinically deﬁned, or possible sIBM. Therewas
also no family history of muscle diseases, and none of the 7 patients
and their families showed evidence of bone or cognitive problems.
Fig. 2 illustrates the pathologic features of muscle biopsies
observed in patients carrying variants in SQSTM1 only because of
the availability of the biopsy images. P62-positive inclusions were
found in 3 patients with SQSTM1. Patients with SQSTM1 variants
showed a global upregulation of MHC-I (diffuse pattern, Fig. 2G)
compared with the healthy control (Fig. 2H).
To further understand molecular changes occurring in sIBM,
particularly those related to the variants in SQSTM1 and VCP, we have
performedwhole-genome expression analysis. Most of the differential
expressed genes were found comparing the SQSTM1 sIBM patient
group with controls (Supplementary Tables 1 and 2), with 33 upre-
gulated and 7 downregulated genes. The small number of available
tissue samples (n ¼ 2) from patients with VCP variants prevented
statistical analysis of this sIBM patient group. The expression of
SQSTM1 and VCP did not show signiﬁcant differences between any
patient group and controls, but a signiﬁcant upregulation of MHC
genes (class I [HLA-A] and class II [CD74 andHLA-DRA]) was seen in the
group of patients carrying SQSTM1 variants (Supplementary Table 2).
RT-qPCR analysis of those MHC genes validated their upregulation inMAF in
ExAC (%)
MAF in sIBM
cohort (%)
GERPþþ
score
PolyPhen prediction Known in other
diseases
0.089 0.275 4.43 Pathogenic Familial PDB and ALS
0.152 0.275 5.17 Benign Early-onset AD
0.0017 0.275 3.65 Possibly damaging d
0.242 0.275 3.87 Possibly damaging ALS
0.054 0.275 5.71 Benign IBMPFD, ALS, and PD
0.00082 0.549 4.62 Possibly damaging IBMPFD, IBM with PD,
and sporadic ALS
E, glutamic acid; ExAC, Exome Aggregation Consortium; G, glycine; GERP, genomic
ease and frontotemporal dementia; K, lysine; L, leucine; MAF, minor allele frequency;
inclusion bodymyositis; SQSTM1, sequestosome 1; V, valine; VCP, valosin-containing
Fig. 1. Mutations and/or variants in sequestosome 1 (SQSTM1) and valosin-containing protein (VCP) genes and their protein domains. (A) Mutations and/or variants found in
SQSTM1 gene and protein domains. (B) Mutations and/or variants found in VCP gene and the protein domains. The ones above the gene structure were reported in the previous
studies. The ones below were identiﬁed in our sporadic inclusion body myositis cohort, and the one labeled in red was not reported in other diseases before. Abbreviations: LIR, LC3-
interaction region; PB1, Phox and Bem1p domain; TRAF6, tumor necrosis factor receptoreassociated factor 6 binding site; UBA, ubiquitin-associated domain; UTR, untranslated
region; ZZ, zinc ﬁnger domain.
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the controls, with signiﬁcant upregulation of all analyzed genes
(Fig. 3). Functional enrichment analysis of upregulated genes in the
SQSTM1 patient group showed a signiﬁcant overrepresentation of
several Gene Ontology terms related with immune response, MHC
protein complex, and endosome vesicles and KEGG pathways mostly
related to inﬂammatory, autoimmune, and infectious diseases
(Supplementary Table 3). The small number of dysregulated genes
found in the expressionmicroarray analysis data prevented functional
enrichment analysis for other comparison groups.
4. Discussion
Using whole-exome sequencing, we identiﬁed rare missense
variants in the SQSTM1 and VCP genes in 7 sIBM cases. Thefrequency of patients with rare SQSTM1 and VCP variants in the
sIBM cohort was 4.0%. Two independent cases have previously been
reported with VCP variants (Weihl et al., 2015), but our study ex-
tends this ﬁnding in a larger cohort of sIBM patients. Regarding
SQSTM1, this is to our knowledge the ﬁrst report where possible
pathogenic variants in this gene are observed in sIBM patients.
The SQSTM1 gene encodes for sequestosome 1 and/or p62
(referred as p62 in the article), which is a multifunction protein
participating in a number of different biological pathways (Komatsu
et al., 2012), including the autophagy pathway and various trans-
duction pathways such as nuclear factor-kappaB signaling and
apoptosis. Mutations in SQSTM1were ﬁrst identiﬁed in PDB (Laurin
et al., 2002), a chronic disease of bone that can cause skeletal
deformity and fractures, and account for 25%e50% of familial and
5%e10% of sporadic PDB patients (Ralston and Layﬁeld, 2012). In
Table 2
Demographic and clinical features of sIBM patients carrying variants in SQSTM1 and VCP genes
Features Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Sex F M M F M F M
Ethnicity Caucasian Caucasian Indian subcontinent Caucasian Caucasian Caucasian Caucasian
Age at onset 45 50 71 57 85 74 48
Family history       
Finger ﬂexor weakness þ þ þ þ þ þ þ
Weakness of KE > HF   þ þ UNK  
Weakness of FF > SA þ þ þ þ UNK þ þ
Weakness of WF >WE þ þ þ  UNK  
PDB       
ALS       
FTD       
Parkinson’s disease       
Elevated CK (ULN) þ (15) þ (15) þ (15)   N/A þ (15)
Neurophysiological investigation Myopathic Myopathic Myopathic N/A UNK N/A N/A
MRC 2010 sIBM diagnostic category PAD PAD PAD CLD PO PO PO
Key: ALS, amyotrophic lateral sclerosis; CK, creatine kinase; CLD, clinically deﬁned; F, female; FF, ﬁnger ﬂexion; FTD, frontotemporal dementia; HF, hip ﬂexion; KE, knee
extension; M, male; N/A, not available; PAD, pathologically deﬁned; PDB, Paget disease of bone; PO, possible; SA, shoulder abduction; sIBM, sporadic inclusion body myositis;
SQSTM1, sequestosome 1; ULN, upper limit of normal; UNK, unknown; VCP, valosin-containing protein; WE, wrist extension; WF, wrist ﬂexion.
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3.5% of patients with ALS/FTD with or without familial history
(Rubino et al., 2012), a similar frequency to the one we found in our
sIBM cohort. Mutations in SQSTM1 are widespread along the gene
(Fig. 1A), but the missense mutation p.P392L located in the C-ter-
minal ubiquitin-associated domain, where most mutations lie in, is
the most frequent SQSTM1 mutation in all the different clinical
phenotypes (Fecto et al., 2011; Laurin et al., 2002). A mouse model
with sqstm1 p.P394L mutation (Daroszewska et al., 2011), equiva-
lent to SQSTM1 p.P392L in humans, developed a human PDB-like
phenotype and showed dysregulation of autophagy and enhanced
autophagosome formation. The SQSTM1 p.K238E has also been re-
ported in one sporadic ALS (Rubino et al., 2012) and lies in a tumor
necrosis factor receptoreassociated factor 6 (TRAF6)ebinding
sitedwhere p62 interacts with TRAF6, a critical component of the
nuclear factor-kappaB pathway in response to multifactors,
including proinﬂammatory cytokines (Fecto et al., 2011). The
SQSTM1 p.G194R has not been observed in other diseases and was
absent in our aged controls, and it is worth mentioning that it has
been found overrepresented our sIBM cohort. Although the SQSTM1
p.A117V is predicted as benign, it was absent in our aged controls
and recently was reported in a patient with early-onset AD (Cuyvers
et al., 2015) and thus cannot be excluded as a risk factor for sIBM.
The VCP gene encodes for the ATPase valosin-containing protein,
which plays a role in proteasomal degradation of misfolded pro-
teins (Meyer and Weihl, 2014). VCP is also involved in critical
signaling pathways, membrane fusion, cell cycle controls, and moreTable 3
Main muscle biopsy features of sIBM patients carrying variants in SQSTM1 and VCP
genes
Muscle biopsy features Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7
Endomysial exudate þ þ þ þ þ þ þ
MHC-I upregulation þ þ þ þ þ þ þ
Partial invasion þ þ þ  þ  
Rimmed vacuoles þ þ þ þ þ  
p62 (sarcoplasmic and
intranuclear inclusions)
þ þ þ N/A N/A N/A N/A
TDP-43 N/A þ N/A N/A N/A N/A N/A
15e18 (or 16e21) nm
ﬁlaments
N/A N/A N/A  N/A N/A N/A
COX-deﬁcient ﬁbers þ þ  þ  þ þ
Key: COX, cytochrome c oxidase; MHC, major histocompatibility complex; N/A, not
available; sIBM, sporadic inclusion bodymyositis; SQSTM1, sequestosome 1; TDP-43,
TAR DNA-binding protein-43; VCP, valosin-containing protein.importantly facilitating a cargo sorting via endosomal and/or
autophagy pathway (Meyer and Weihl, 2014). Mutations in VCP are
known to cause IBMPFD (Watts et al., 2004), Parkinson’s disease
(Majounie et al., 2012), and are also associated with ALS with or
without FTD (Johnson et al., 2010). The VCP p.I27V variant has been
previously reported as potentially pathogenic (Majounie et al.,
2012; Rohrer et al., 2011) and was recently found in another pa-
tient with sIBM (Weihl et al., 2015). Functional analysis of this
variant showed an increase in p62 and LC3II protein levels (Weihl
et al., 2015), suggesting it may cause disruption in autophago-
some maturation (Ju et al., 2009). The VCP p.R159C found to be
overrepresented in our sIBM cohort has been previously reported as
pathogenic and associated with IBMPFD (Bersano et al., 2009) and
sporadic ALS (Abramzon et al., 2012). Two additional mutations
were also found at this amino acid residue in familial ALS (p.R159G)
(Johnson et al., 2010) and IBMPFD (p.R159H) (Haubenberger et al.,
2005). The VCP p.R159C lies within the highly conserved CDC48
domain of the protein (Fig. 1B), which is involved in ubiquitin-
binding and protein-protein interaction, and a hotspot for VCP
mutations (Bersano et al., 2009).
We reviewed the clinical and pathologic details of all sIBM pa-
tients with SQSTM1 and VCP variants and conﬁrmed that none of
them had developed symptoms of PDB, FTD, or ALS and none had
family history of these diseases or family history of muscle weak-
ness. VCP staining was not available for all the patients, but p62-
positive inclusions were seen in all 3 biopsies where p62 staining
was available, including 3 sIBM with SQSTM1 p.P392L, p.A117V, and
p.G194R.
The expression levels of either SQSTM1 or VCP messenger RNA
were not signiﬁcantly altered in patients compared with controls,
suggesting that the missense variants found in these patients did
not alter the corresponding gene expression at the messenger RNA
level. P62 and VCP aggregates in the muscle could be a result of
increased protein stability, dysfunction of other factors along the
proteasomal or lysosomal pathway, or both (Sandri, 2010).
The MHC class I (HLA-A) and II (HLA-DRA) genes were signiﬁ-
cantly upregulated in patients compared with controls by RT-qPCR,
which is consistent with a previous study (Ivanidze et al., 2011), and
the other MHC class II gene (CD74) was signiﬁcantly upregulated
only in the SQSTM1 patient group. The statistical analysis could not
be carried out for the VCP patient group because of small sample
size, but there was also a trend for the upregulation of these
inﬂammation markers. The more pronounced upregulation
observed in the SQSTM1 sIBM patient group than in the VCP patient
Fig. 2. Pathologic features observed in sporadic inclusion body myositis patients. There was variation in ﬁber size with endomysial inﬂammation, increased internal nucleation, and
ﬁber regeneration (A, hematoxylin and eosin). Rimmed vacuoles were found in all cases (B, Gomori trichrome). The inﬂammatory inﬁltrate contains T lymphocytes (C, CD3). A
ragged red ﬁber was observed in case 2 (D, Gomori trichrome). Cytochrome c oxidase negative ﬁbers were identiﬁed (E, cytochrome oxidase and/or succinic dehydrogenase). P62
immunoreactive sarcoplasmic inclusions were identiﬁed (F) in addition to sparse intranuclear inclusions (arrow and inset). Major histocompatibility complex class I was diffusely
increased in patients with sequestosome 1 (SQSTM1) variants (G) in comparison with a normal control (H). Scale bar represents 50 mm in A, C, G, and H; 25 mm in B, D, and F; and
10 mm in the inset in F. Panels A and G are from Case 1; panels BeF are from case 2.
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Fig. 3. Scatter plot illustrating distribution of the fold change for the expression of 3
major histocompatibility complex genes in sporadic inclusion body myositis groups
compared with controls as determined by real-time quantitative polymerase chain
reaction. All expression levels were normalized to the expression of the reference gene,
PPIA, and relative to the mean normalized expression of all the controls. The solid black
lines denote the medians. Only signiﬁcant Mann-Whitney U test p values (<0.05)
regarding comparisons of patient groups with controls are shown. Abbreviations:
CD74, CD74 molecule, major histocompatibility complex, class II invariant chain; HLA-
A, major histocompatibility complex, class I, A; HLA-DRA, major histocompatibility
complex, class II, DR alpha.
Q. Gang et al. / Neurobiology of Aging 47 (2016) 218.e1e218.e9 218.e7group. This is the ﬁrst time that different expression level of
inﬂammation markers between patients with sIBM is suggested.
Although further cases should be analyzed, the MHC expression
could be a potential differentiating factor that directs the clinical
phenotype of SQSTM1 or VCP toward sIBM as opposed to the other
neurodegenerative conditions. Additional analysis in muscle and
other tissues of patients carrying SQSTM1 or VCPmutations without
symptomatic sIBM but other phenotypes is also necessary in the
future to conﬁrm this hypothesis.
In conclusion, we report for the ﬁrst time likely pathogenic
SQSTM1 variants and expand the spectrum of VCP variants in sIBM.Our ﬁndings suggest that variants in these genes constitute genetic
susceptibility factors for sIBM and for other multisystem protein-
opathy phenotypes. The ﬁndings from this study also expand the
clinicopathologic spectrum of diseases associated with SQSTM1 and
VCP genes, and the overlap between sIBM and IBMPFD, ALS, and/or
FTD suggests that muscle and brain diseases share similar patho-
genic pathways that may be important for further biomarkers,
genes, and therapeutic target discovery. Further investigation of the
sIBM whole-exome sequencing data is still ongoing and data from
this international collaboration will likely reveal further ﬁndings.
Disclosure statement
Declaration of interests: All authors have no competing ﬁnancial
interests. Authors’ contributions: Qiang Gang contributed to sample
collection, all the experimental work, data analysis, and drafting the
ﬁrst version of the manuscript; Conceição Bettencourt contributed
to the experimental plans of microarray and RT-qPCR, preliminary
analysis of microarray data, and statistical plan; Pedro M. Machado
contributed to overall coordination of the study, namely worldwide
sample collection and liaising with all the study collaborators;
Conceição Bettencourt, PedroM. Machado, and Henry Houlden also
contributed to drafting the ﬁrst version of the manuscript; Janice L.
Holton contributed to the review and photography of the muscle
biopsies; Alan M. Pittman and Deborah Hughes contributed to the
generation of whole-exome sequencing data; Stefen Brady, Janice L.
Holton, and Boel De Paepe contributed to immunotyping of muscle
biopsies; and Andrew B. Singleton contributed to the exome data
from control individuals. All the authors from International IBM
Genetic Consortium and Muscle Study Group contributed to
acquisition of clinical data and sample collection. Michael G. Hanna,
Henry Houlden, and Pedro M. Machado are principal investigators
of the International IBM Consortium Genetics Study. All the authors
contributed to the critical revision of the manuscript and approved
the ﬁnal version.
Acknowledgements
Qiang Gang is supported by a University College London (UCL)
Impact Studentship and a scholarship from the Chinese Scholarship
Council. Conceição Bettencourt is supported by the Wellcome Trust.
Pedro M. Machado is supported by the National Institute for Health
Research (NIHR) Rare Diseases Translational Research Collaboration
and by the NIHR University College London Hospitals (UCLH)
Biomedical Research Centre (BRC). Michael G. Hanna is supported by
an MRC Centre grant 2013e2018 (MR/K000608/01). The Interna-
tional IBM Consortium Genetic Study is also supported by an MRC
grant (MR/J004758/1). We thank all the study collaborators from UK,
USA, Australia, Europe, and Brazil and especially thank all the pa-
tients and their families for participating in our study. This publica-
tion was supported by researchers at the UCL/UCLH NIHR BRC. We
wish to acknowledge the National Institute of Health, USA, for
providing the neuropathologically healthy control exomes. We also
wish to acknowledge theQueen Square Brain Bank in London and the
MRC Sudden Death Brain and Tissue Bank in Edinburgh, UK, which
provided us the control tissues. We also wish to acknowledge col-
leagues from the UCL Department of Pathology and Boel De Paepe for
providing the muscle biopsy slides. We also wish to acknowledge
“The BioBank of Skeletal Muscle, Nerve Tissue, DNA and Cell Lines”
and “The Biobank Cells, Tissue and DNA from Patients with Neuro-
muscular Diseases” that provided us with case specimens. Both are
members of the Telethon Network of Genetic Biobanks (grant
number GTB12001), funded by Telethon Italy and the EuroBioBank
network. We also acknowledge all the participants of the Interna-
tional IBM Genetics Consortium and the Muscle Study Group, who
Q. Gang et al. / Neurobiology of Aging 47 (2016) 218.e1e218.e9218.e8have endorsed this projectdMichael G. Hanna, Henry Houlden,
PedroM.Machado, Qiang Gang, Conceicao Bettencourt, Estelle Healy,
Matthew Parton, and Janice L. Holton: Department of Molecular
Neuroscience and MRC Centre for Neuromuscular Diseases, Institute
of Neurology, University College London, Queen Square, London, UK;
Stefen Brady and David Hilton-Jones: Nufﬁeld Department of Clinical
Neurosciences, University of Oxford, UK; Perry B. Shieh: Neuromus-
cular Division, Department of Neurology, UCLA Medical Centre, USA;
Edmar Zanoteli and Leonardo Valente de Camargo: Department of
Neurology, Medical School of the University of São Paulo (FMUSP),
São Paulo, Brazil; Boel De Paepe and Jan De Bleecker: Ghent Uni-
versity Hospital, Department of Neurology and Neuromuscular
Reference Centre, Ghent, Belgium; Aziz Shaibani: Nerve and Muscle
Centre of Texas, Houston, TX, USA; Michela Ripolone, Raffaella Vio-
lano, and Maurizio Moggio: Neuromuscular Unit, IRCCS Foundation
Ca’ Granda Ospedale Maggiore Policlinico, Dino Ferrari Centre, Uni-
versity of Milan, Milan, Italy; Richard J. Barohn, MazenM. Dimachkie,
April L. McVey, Mamatha Pasnoor, Melanie Glenn, Omar Jawdat,
Jeffrey Statland, and Gabrielle Rico: The University of Kansas Medical
Centre, Kansas City, USA; Marina Mora, Renato Mantegazza, and
Simona Zanotti: Neuromuscular Diseases and Neuroimmunology
Unit, Fondazione IRCCS Isitituto Neurologico C. Besta, Milano, Italy;
Merrilee Needham and Frank Mastaglia: Western Australian Neuro-
sciences Research Institute, University of Western Australia and
Murdoch University, Fiona Stanley Hospital, Perth, Australia; Chris-
tina Liang: Royal North Shore Hospital, New South Wales, Australia;
Marinos C. Dalakas and Angie Biba: Neuroimmunology Unit,
Department of Pathophysiology, National University of Athens
Medical School, Athens, Greece; Hector Chinoy and James B. Lilleker:
Centre for Musculoskeletal Research, Institute of Inﬂammation and
Repair, Faculty of Medical and Human Sciences, University of Man-
chester, Manchester, UK; Janine Lamb and Hazel Platt: Centre for
Integrated GenomicMedical Research, Institute of Population Health,
Faculty of Medical and Human Sciences, University of Manchester,
Manchester, UK; Robert G. Cooper: MRC/ARUK Institute for Ageing
and Chronic Disease, University of Liverpool, Liverpool, UK; James
A.L.Miller: Department of Neurology, Newcastle UponTyneHospitals
NHS Trust, UK; Mark Roberts: Salford Royal NHS Foundation Trust,
UK; ElizabethHouseham, David Hilton, and Aditya Shivane: Derriford
Hospital, Plymouth, UK; Amy Bartlett and John T. Kissel: The Ohio
State University Wexner Medical Center, USA; Heidi Runk and
Matthew Wicklund: Penn State Milton S. Hershey Medical Center,
USA; and David S. Saperstein and Lynette R. McKinney: Phoenix
Neurological Associates, USA.Appendix A. Supplementary data
Supplementary data related to this article can be found, in the on-
line version, at http://dx.doi.org/10.1016/j.neurobiolaging.2016.07.024.References
Abramzon, Y., Johnson, J.O., Scholz, S.W., Taylor, J.P., Brunetti, M., Calvo, A.,
Mandrioli, J., Benatar, M., Mora, G., Restagno, G., Chio, A., Traynor, B.J., 2012.
Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral
sclerosis. Neurobiol. Aging 33, 2231.e1e2231.e6.
Adzhubei, I.A., Schmidt, S., Peshkin, L., Ramensky, V.E., Gerasimova, A., Bork, P.,
Kondrashov, A.S., Sunyaev, S.R., 2010. A method and server for predicting
damaging missense mutations. Nat. Methods 7, 248e249.
Badrising, U.A., Maat-Schieman, M., van Duinen, S.G., Breedveld, F., van Doorn, P.,
van Engelen, B., van den Hoogen, F., Hoogendijk, J., Howeler, C., de Jager, A.,
Jennekens, F., Koehler, P., van der Leeuw, H., de Visser, M., Verschuuren, J.J.,
Wintzen, A.R., 2000. Epidemiology of inclusion body myositis in The
Netherlands: a nationwide study. Neurology 55, 1385e1387.
Bersano, A., Del Bo, R., Lamperti, C., Ghezzi, S., Fagiolari, G., Fortunato, F., Ballabio, E.,
Moggio, M., Candelise, L., Galimberti, D., Virgilio, R., Lanfranconi, S., Torrente, Y.,
Carpo, M., Bresolin, N., Comi, G.P., Corti, S., 2009. Inclusion body myopathy and fron-
totemporal dementia causedbyanovel VCPmutation.Neurobiol. Aging30, 752e758.Brady, S., Squier, W., Sewry, C., Hanna, M., Hilton-Jones, D., Holton, J.L., 2014.
A retrospective cohort study identifying the principal pathological features
useful in the diagnosis of inclusion body myositis. BMJ Open 4, e004552.
Bucelli, R.C., Arhzaouy, K., Pestronk, A., Pittman, S.K., Rojas, L., Sue, C.M., Evila, A.,
Hackman, P., Udd, B., Harms, M.B., Weihl, C.C., 2015. SQSTM1 splice site muta-
tion in distal myopathy with rimmed vacuoles. Neurology 85, 665e674.
Chan, N., Le, C., Shieh, P., Mozaffar, T., Khare, M., Bronstein, J., Kimonis, V., 2012.
Valosin-containing protein mutation and Parkinson’s disease. Parkinsonism
Relat. Disord. 18, 107e109.
Cuyvers, E., van der Zee, J., Bettens, K., Engelborghs, S., Vandenbulcke, M.,
Robberecht, C., Dillen, L., Merlin, C., Geerts, N., Graff, C., Thonberg, H.,
Chiang, H.H., Pastor, P., Ortega-Cubero, S., Pastor, M.A., Diehl-Schmid, J.,
Alexopoulos, P., Benussi, L., Ghidoni, R., Binetti, G., Nacmias, B., Sorbi, S.,
Sanchez-Valle, R., Llado, A., Gelpi, E., Almeida, M.R., Santana, I., Clarimon, J.,
Lleo, A., Fortea, J., de Mendonca, A., Martins, M., Borroni, B., Padovani, A.,
Matej, R., Rohan, Z., Ruiz, A., Frisoni, G.B., Fabrizi, G.M., Vandenberghe, R., De
Deyn, P.P., Van Broeckhoven, C., Sleegers, K., 2015. Genetic variability in SQSTM1
and risk of early-onset Alzheimer dementia: a European early-onset dementia
consortium study. Neurobiol. Aging 36, 2005.e15e2005.e22.
Dabby, R., Lange, D.J., Trojaborg, W., Hays, A.P., Lovelace, R.E., Brannagan, T.H.,
Rowland, L.P., 2001. Inclusion body myositis mimicking motor neuron disease.
Arch. Neurol. 58, 1253e1256.
Daroszewska, A., van ’t Hof, R.J., Rojas, J.A., Layﬁeld, R., Landao-Basonga, E., Rose, L.,
Rose, K., Ralston, S.H., 2011. A point mutation in the ubiquitin-associated
domain of SQSMT1 is sufﬁcient to cause a Paget’s disease-like disorder in
mice. Hum. Mol. Genet. 20, 2734e2744.
Davydov, E.V., Goode, D.L., Sirota, M., Cooper, G.M., Sidow, A., Batzoglou, S., 2010.
Identifying a high fraction of the human genome to be under selective
constraint using GERPþþ. PLoS Comput. Biol. 6, e1001025.
Fecto, F., Yan, J., Vemula, S.P., Liu, E., Yang, Y., Chen, W., Zheng, J.G., Shi, Y.,
Siddique, N., Arrat, H., Donkervoort, S., Ajroud-Driss, S., Suﬁt, R.L., Heller, S.L.,
Deng, H.X., Siddique, T., 2011. SQSTM1 mutations in familial and sporadic
amyotrophic lateral sclerosis. Arch. Neurol. 68, 1440e1446.
Gang, Q., Bettencourt, C., Machado, P., Hanna, M.G., Houlden, H., 2014. Sporadic
inclusion body myositis: the genetic contributions to the pathogenesis.
Orphanet J. Rare Dis. 9, 88.
Gang, Q., Bettencourt, C., Machado, P.M., Fox, Z., Brady, S., Healy, E., Parton, M.,
Holton, J.L., Hilton-Jones, D., Shieh, P.B., Zanoteli, E., De Paepe, B., De Bleecker, J.,
Shaibani, A., Ripolone, M., Violano, R., Moggio, M., Barohn, R.J., Dimachkie, M.M.,
Mora, M., Mantegazza, R., Zanotti, S., Hanna, M.G., Houlden, H., 2015. The effects
of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic in-
clusion body myositis. Neurobiol. Aging 36, 1766.e1e1766.e3.
Gidaro, T., Modoni, A., Sabatelli, M., Tasca, G., Broccolini, A., Mirabella, M., 2008. An
Italian family with inclusion-body myopathy and frontotemporal dementia due
to mutation in the VCP gene. Muscle Nerve 37, 111e114.
Griggs, R.C., Askanas, V., DiMauro, S., Engel, A., Karpati, G., Mendell, J.R., Rowland, L.P.,
1995. Inclusion body myositis and myopathies. Ann. Neurol. 38, 705e713.
Haubenberger, D., Bittner, R.E., Rauch-Shorny, S., Zimprich, F., Mannhalter, C.,
Wagner, L., Mineva, I., Vass, K., Auff, E., Zimprich, A., 2005. Inclusion body
myopathy and Paget disease is linked to a novel mutation in the VCP gene.
Neurology 65, 1304e1305.
Hilton-Jones, D., Miller, A., Parton, M., Holton, J., Sewry, C., Hanna, M.G., 2010. In-
clusion body myositis: MRC Centre for Neuromuscular diseases, IBM workshop,
London, 13 June 2008. Neuromuscul. Disord. 20, 142e147.
Ivanidze, J., Hoffmann, R., Lochmuller, H., Engel, A.G., Hohlfeld, R., Dornmair, K.,
2011. Inclusion body myositis: laser microdissection reveals differential up-
regulation of IFN-gamma signaling cascade in attacked versus nonattacked
myoﬁbers. Am. J. Pathol. 179, 1347e1359.
Johnson, J.O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V.M.,
Trojanowski, J.Q., Gibbs, J.R., Brunetti, M., Gronka, S., Wuu, J., Ding, J.,
McCluskey, L., Martinez-Lage, M., Falcone, D., Hernandez, D.G., Arepalli, S.,
Chong, S., Schymick, J.C., Rothstein, J., Landi, F., Wang, Y.D., Calvo, A., Mora, G.,
Sabatelli, M., Monsurro, M.R., Battistini, S., Salvi, F., Spataro, R., Sola, P.,
Borghero, G., Galassi, G., Scholz, S.W., Taylor, J.P., Restagno, G., Chio, A.,
Traynor, B.J., 2010. Exome sequencing reveals VCP mutations as a cause of fa-
milial ALS. Neuron 68, 857e864.
Ju, J.S., Fuentealba, R.A., Miller, S.E., Jackson, E., Piwnica-Worms, D., Baloh, R.H.,
Weihl, C.C., 2009. Valosin-containing protein (VCP) is required for autophagy
and is disrupted in VCP disease. J. Cell. Biol. 187, 875e888.
Komatsu, M., Kageyama, S., Ichimura, Y., 2012. p62/SQSTM1/A170: physiology and
pathology. Pharmacol. Res. 66, 457e462.
Koppers, M., van Blitterswijk, M.M., Vlam, L., Rowicka, P.A., van Vught, P.W.J.,
Groen, E.J.N., Spliet, W.G.M., Engelen-Lee, J., Schelhaas, H.J., de Visser, M., van
der Kooi, A.J., van der Pol, W.L., Pasterkamp, R.J., Veldink, J.H., van den Berg, L.H.,
2012. VCP mutations in familial and sporadic amyotrophic lateral sclerosis.
Neurobiol. Aging 33, 837.e7e837.e13.
Kumar, P., Henikoff, S., Ng, P.C., 2009. Predicting the effects of coding non-synony-
mous variants on protein function using the SIFT algorithm. Nat. Protoc 4,
1073e1081.
Kwok, C.T., Morris, A., de Belleroche, J.S., 2014. Sequestosome-1 (SQSTM1) sequence
variants in ALS cases in the UK: prevalence and coexistence of SQSTM1
mutations in ALS kindred with PDB. Eur. J. Hum. Genet. 22, 492e496.
Laurin, N., Brown, J.P., Morissette, J., Raymond, V., 2002. Recurrent mutation of the
gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am. J.
Hum. Genet. 70, 1582e1588.
Q. Gang et al. / Neurobiology of Aging 47 (2016) 218.e1e218.e9 218.e9Le Ber, I., Camuzat, A., Guerreiro, R., Bouya-Ahmed, K., Bras, J., Nicolas, G.,
Gabelle, A., Didic, M., De Septenville, A., Millecamps, S., Lenglet, T.,
Latouche, M., Kabashi, E., Campion, D., Hannequin, D., Hardy, J., Brice, A.,
2013. SQSTM1 mutations in French patients with frontotemporal dementia
or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neu-
rol. 70, 1403e1410.
Lotz, B.P., Engel, A.G., Nishino, H., Stevens, J.C., Litchy, W.J., 1989. Inclusion body
myositis. Observations in 40 patients. Brain 112, 727e747.
Machado, P.M., Dimachkie, M.M., Barohn, R.J., 2014. Sporadic inclusion body
myositis: new insights and potential therapy. Curr. Opin. Neurol. 27, 591e598.
Majounie, E., Traynor, B.J., Chio, A., Restagno, G., Mandrioli, J., Benatar, M., Taylor, J.P.,
Singleton, A.B., 2012. Mutational analysis of the VCP gene in Parkinson’s disease.
Neurobiol. Aging 33, 209.e1e209.e2.
Mencacci, N.E., Rubio-Agusti, I., Zdebik, A., Asmus, F., Ludtmann, M.H., Ryten, M.,
Plagnol, V., Hauser, A.K., Bandres-Ciga, S., Bettencourt, C., Forabosco, P., Hughes, D.,
Soutar, M.M., Peall, K., Morris, H.R., Trabzuni, D., Tekman, M., Stanescu, H.C.,
Kleta, R., Carecchio, M., Zorzi, G., Nardocci, N., Garavaglia, B., Lohmann, E.,
Weissbach, A., Klein, C., Hardy, J., Pittman, A.M., Foltynie, T., Abramov, A.Y.,
Gasser, T., Bhatia, K.P., Wood, N.W., 2015. A missense mutation in KCTD17 causes
autosomal dominant myoclonus-dystonia. Am. J. Hum. Genet. 96, 938e947.
Meyer, H., Weihl, C.C., 2014. The VCP/p97 system at a glance: connecting cellular
function to disease pathogenesis. J. Cell. Sci. 127, 3877e3883.
Miller, L., Rollinson, S., Callister, J.B., Young, K., Harris, J., Gerhard, A., Neary, D.,
Richardson, A., Snowden, J., Mann, D.M.A., Pickering-Brown, S.M., 2015. p62/SQSTM1
analysis in frontotemporal lobardegeneration.Neurobiol. Aging36,1603.e5e1603.e9.
Ralston, S.H., Layﬁeld, R., 2012. Pathogenesis of Paget disease of bone. Calciﬁed
Tissue Int. 91, 97e113.
Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., 2015. Limma
powers differential expression analyses for RNA-sequencing and microarray
studies. Nucleic Acids Res. 43, e47.Rohrer, J.D., Warren, J.D., Reiman, D., Uphill, J., Beck, J., Collinge, J., Rossor, M.N.,
Isaacs, A.M., Mead, S., 2011. A novel exon 2 I27V VCP variant is associated with
dissimilar clinical syndromes. J. Neurol. 258, 1494e1496.
Rubino, E., Rainero, I., Chio, A., Rogaeva, E., Galimberti, D., Fenoglio, P.,
Grinberg, Y., Isaia, G., Calvo, A., Gentile, S., Bruni, A.C., St George-Hyslop, P.H.,
Scarpini, E., Gallone, S., Pinessi, L., 2012. SQSTM1 mutations in fronto-
temporal lobar degeneration and amyotrophic lateral sclerosis. Neurology
79, 1556e1562.
Sandri, M., 2010. Autophagy in skeletal muscle. FEBS Lett. 584, 1411e1416.
Scheetz, T.E., Roos, B.R., Solivan-Timpe, F., Miller, K., DeLuca, A.P., Stone, E.M.,
Kwon, Y.H., Alward, W.L.M., Wang, K., Fingert, J.H., 2016. SQSTM1 mutations and
glaucoma. PLoS One 11, e0156001.
Schmittgen, T.D., Livak, K.J., 2008. Analyzing real-time PCR data by the comparative
C(T) method. Nat. Protoc. 3, 1101e1108.
Schwarz, J.M., Cooper, D.N., Schuelke, M., Seelow, D., 2014. MutationTaster2: mu-
tation prediction for the deep-sequencing age. Nat. Methods 11, 361e362.
Tawil, R., Griggs, R.C., 2002. Inclusion body myositis. Curr. Opin. Rheumatol. 14,
653e657.
Trabzuni, D., Ryten, M., Walker, R., Smith, C., Imran, S., Ramasamy, A., Weale, M.E.,
Hardy, J., 2011. Quality control parameters on a large dataset of regionally
dissected human control brains for whole genome expression studies.
J. Neurochem. 119, 275e282.
Watts, G.D., Wymer, J., Kovach, M.J., Mehta, S.G., Mumm, S., Darvish, D., Pestronk, A.,
Whyte, M.P., Kimonis, V.E., 2004. Inclusion body myopathy associated with
Paget disease of bone and frontotemporal dementia is caused by mutant
valosin-containing protein. Nat. Genet. 36, 377e381.
Weihl, C.C., Baloh, R.H., Lee, Y., Chou, T.F., Pittman, S.K., Lopate, G., Allred, P.,
Jockel-Balsarotti, J., Pestronk, A., Harms, M.B., 2015. Targeted sequencing and
identiﬁcation of genetic variants in sporadic inclusion body myositis.
Neuromuscul Disord. 25, 289e296.
